Navigation Links
Brodalumab demonstrates significant clinical response in psoriatic arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis (PsA).

PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in up to 30% of those of cases.3

IL-17 induces production of anti-microbial peptides and pro-inflammatory cytokines that in turn may help sustain immune responses in the skin.4 With similar pathways impacting skin and joint diseases, data suggest that cytokine-targeting strategies aimed at blocking signalling through the IL-17 receptor may be a beneficial new strategy in the treatment of PsA.

Lead author of the study Dr Mease, Swedish Medical Center and University of Washington, Seattle, US commented "PsA is a progressive disease associated with a number of co-morbidities, disability and disfigurement. There is a need for therapies to better manage patient outcomes, and prevent long-term bone loss and permanent joint damage, especially in those patients for whom anti-TNF therapy is not effective or tolerated." Dr Mease continued, "these significant patient responses support continued evaluation of brodalumab for the treatment of PsA and clearly show that cytokine-targeting strategies aimed at blocking signalling through the IL-17 receptor may represent an important new treatment strategy."

The study involving 168 patients with at least a 6 month history of PsA demonstrated that 37% and 39% of subjects in the 140- and 280-mg brodalumab groups respectively, achieved the primary endpoint of ACR20* response rates at week 12 compared with 18% of subjects in the placebo group (p <0.05).

A further analysis determined the ACR20 response rates in biologic-nave subjects were 36% in the 140 mg group, 37% in the 280 mg group, and 20% in the placebo group; comparable with the respective rates of 37%, 42%, and 16%, in subjects with prior biologic exposure. There were consistent improvements in secondary endpoints including ACR50, DAS 28 and components of the ACR including CRP.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Automated insulin dosage titration system demonstrates positive clinical study results
3. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
4. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
5. A study demonstrates that ibuprofen improves bone repair after surgery or a fracture
6. Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
7. Novel technique demonstrates interactions between malaria parasite and HIV
8. New Video Demonstrates Skin Cancer Self-Exam
9. 23andMe demonstrates comprehensive research capabilities at annual meeting for ASHG
10. Study demonstrates that earlier end of life care discussions are linked to less aggressive care in final days of life
11. Study demonstrates health benefits of coming out of the closet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... Livionex, Inc., a ... of a double blind clinical study for its dental gel that shows significant reduction ... brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... and breast cancer survivor Sandra Lee as keynote speaker for the 34th Annual ... Florida. , In making the announcement, PER® president, Phil Talamo, said, “We are ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a ... announced a new agreement as part of a long-term extension of their media partnership. ... the airing of some of the sport’s premier events exclusively on FloWrestling.com as well ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide ... recognized leader in the fast-casual category, announces a hearty and wholesome Winter Menu. ... Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 North America Insulin ... new report, "North America Insulin Delivery Market Outlook to ... Insulin Delivery market. The report provides value, in millions ... (USD) within market segments - Insulin Pens, Insulin Pumps, ... report also provides company shares and distribution shares data ...
(Date:1/17/2017)... Jan. 17, 2017 The interventional radiology products ... 2021 from USD 6.35 billion in 2016, at a ... growth of this market are rising incidence of chronic ... invasive surgeries. The global interventional radiology products ... region. On the basis of type, the stents segment ...
(Date:1/17/2017)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... Phase 3 clinical trial comparing the efficacy and safety ... prevention of hepatic veno-occlusive disease (VOD) in adult and ... are at high risk or at very high risk ... conducted across approximately 100 medical centers in ...
Breaking Medicine Technology: